Far-right motion relating to pandemic scandal threatens to derail European Commission president’s second-term agenda ...

Pfizer’s Q1 earnings call delivered a rollercoaster of cautious optimism. CEO Albert Bourla credited solid execution in ...

Pfizer’s first quarter results drew a positive market response as management emphasized margin improvement and disciplined ...

Pharma companies met with the Trump administration earlier this month to try and defer implementation of the executive order ...

The Health Secretary's attended the Bilderberg Meeting in Sweden, sipping champagne in the company of billionaires, bankers ...

The Health Secretary's attended the Bilderberg Meeting in Sweden, sipping champagne in the company of billionaires, bankers ...

Pfizer’s 7%+ yield is tempting, but rising political, regulatory, and business risks threaten its stability and growth ...

Pfizer is undervalued as markets fixate on its patent cliff, overlooking strong cash flows, pipeline upside, and a 7% yield.

PwC analysts have warned the speedy evolution of the Chinese biotech sector is creating “heightened risks related to IP ...

The president wants foreign countries to pay more for drugs made in the US to help Big Pharma firms make more money abroad.

The decision of the General Court of the European Union in the Pfizergate case would allow the European Commission to ...

Britain faces paying more for US drugs as part of a deal to avoid future tariffs from Donald Trump. The NHS will review drug ...